Deep Brain Stimulation Probes New Frontiers

27 Sep 2013

Deep brain stimulation (DBS) currently comprises only about a quarter of the worldwide neuromodulation device market, but growth in this segment is strong. Both large and small competitors have targeted DBS, which has the potential to address a number of highly prevalent and underserved diseases and disorders.

Deep brain stimulation (DBS) devices, on the market for 20 years, have enabled the successful treatment of more than 100,000 patients worldwide with debilitating and increasingly prevalent neurological disorders such as Parkinson's disease (PD), essential tremor, dystonia, and epilepsy. But despite two decades of clinical and real-world experience, the full potential of the "brain pacemaker" market is just beginning to emerge, thanks to aggressive research and development efforts by the big players in this space. Over the past few months, new long-term data have been released that will help fuel growth in this market as two cardiac and neurotechnology device giants – St. Jude Medical Inc. and Boston Scientific Corp. – prepare to challenge worldwide neuromodulation leader Medtronic PLC with competitive, next-generation DBS systems. (Also see Also see "Neuromodulation Market: Innovation Brings High-Growth Rewards" - Medtech Insight, 27 March, 2013. and Also see "Emerging Peripheral Nerve Technologies Draw New Competitors To Neuromodulation Market" - Medtech Insight, 26 April, 2013.).

What's more, there are many exciting new companies and technologies entering the scene with the goal of expanding DBS to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Final Chance To Have Your Say: Take Our Reader Survey This Week

17 Sep 2024

• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

04 Sep 2024

• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

22 Aug 2024

• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

09 Jul 2024

• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

Panel: FDA’s Home Healthcare Initiative Holds Promise, But Challenges Remain

06 Jun 2025

• By Elizabeth Orr

During a recent FDLI panel, experts discussed the FDA's Home Healthcare initiative, highlighting its potential benefits and challenges. Key issues include usability testing, reimbursement, labeling for home use, and the need for innovation while ensuring patient safety.